focus -WSS

focus

author：explore 2025-09-29 22:49:46 - browse：36164

Most everything is looking up for Orexo, the company reported on its second quarter earnings call on Tuesday. That is, everything but its digital therapies pipeline.

The Swedish pharmaceutical company, which makes almost all of its money from U.S. sales of its drug for opioid dependence, notched a number of important victories in the quarter: It successfully defended its patents in a case against Sun Pharmaceuticals, it resolved a packaging issue that was holding up the approval of its long-acting rescue medication, and it grew revenues for Zubsolv, its most important product. The company trimmed its losses to 12.6 million SEK, or $1.2 million, and executives reported that with fewer one-time expenses on the horizon, profitability was “in sight.”

“We are at an exciting turning point for the company and I hope our self confidence and optimism is something that you can share,” CEO Nikolaj Sørensen said on the company’s earnings call while cautioning that “there’s a lot more work to be done.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Continuity nursing helped my family in our darkest PICU moments
Next article： Kansas bar where gunfire wounded 9 last month closes permanently

WSS

How Medicaid coverage policies for immigrants impact new moms

A public scorecard can help hold safety

Tuberculosis patients need more than just free medication

Flash flood warnings continue for parts of Missouri, Illinois

Medicare has a new plan to address drug shortages

Google and Epic fight stronger regulation of AI in health care

hotspot

focus

entertainment

DIEP, the 'gold standard' of breast reconstruction, is under threat

STAT Virtual Event: The State of Biosimilars: What to Watch

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Doctors push to include dialysis machines in emergency stockpile

The cancer drug shortage isn’t new — and neither are the solutions

Listen: Wegovy in the brain & pivotal Alzheimer's data

Medicare details structure of new drug price negotiation program

Many breast cancer patients receive more radiation than needed

What does generative AI mean for health care? We asked experts

Rescued Australian man who was adrift 3 months in Pacific with dog 'grateful' to be alive

entertainment

Russia promises retaliation after Ukrainian drones hit a Russian tanker in 2nd sea attack in a day

Why hospitals are withdrawing from US News rankings

With heat waves through August, officials warn of health risks

With heat waves through August, officials warn of health risks

AI can’t replace a physician’s gut feeling

FDA approves RSV monoclonal antibody for infants, toddlers

focus

Wikipedia

leisure time

leisure time